Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | S100A4 | P26447 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29512805 | 1.00 | TDP1 (0.50) | TDP1GPR35ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL28869964 | 0.85 | TDP1 (0.41) | TDP1GPR35ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL3010961 | 0.84 | TDP1 (0.61) | TDP1GPR35ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL30776832 | 0.83 | ALDH1A1 (0.46) | TDP1GPR35ALDH1A1S100A4MAPT | |
| SCHEMBL26164165 | 0.83 | ALDH1A1 (0.46) | TDP1GPR35ALDH1A1S100A4MAPT | |
| Ammonia Solution, Strong SCHEMBL28763100 | 0.82 | TDP1 (0.58) | TDP1GPR35ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL29565836 | 0.82 | ALDH1A1 (0.44) | TDP1GPR35ALDH1A1S100A4MAPT | |
| SCHEMBL26164181 | 0.82 | ALDH1A1 (0.44) | TDP1GPR35ALDH1A1S100A4MAPT | |
| SCHEMBL22325849 | 0.82 | HSPB1 (0.42) | TDP1GPR35ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL16797435 | 0.81 | TDP1 (0.45) | TDP1ALDH1A1TSHRSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 981 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119912430-A | Compound for targeted degradation of p300/CBP protein and synthetic method and application thereof | 复旦大学 | 2025-05-02 | — | — | CN | claimed |
| CN-118684581-A | Method for preparing ultra-high purity 3-bromo-2-fluoronitrobenzene by coupling melt crystallization | 天津科技大学 | 2024-09-24 | — | — | CN | claimed |
| CN-110305018-B | Preparation method of 3-bromo-2-fluoronitrobenzene | 浙江普洛家园药业有限公司 | 2022-07-15 | — | — | CN | claimed |
| CN-107325092-B | Novel preparation process of azithromycin | 山东鲁宁药业有限公司 | 2021-01-08 | — | — | CN | claimed |
| CN-110446704-A | Process for the preparation of sulfonamide-structured kinase inhibitors | ORION CORP | 2019-11-12 | — | — | CN | claimed |
| CN-110305018-A | A kind of preparation method of the bromo- 2- fluoronitrobenzene of 3- | 浙江普洛家园药业有限公司 | 2019-10-08 | — | — | CN | claimed |
| CN-109354569-A | A kind of preparation method of the bromo- 4- fluorobenzene of 1,3- bis- | 常州大学 | 2019-02-19 | — | — | CN | claimed |
| CN-107325092-A | A kind of new preparation process of Azilsartan | 山东鲁宁药业有限公司 | 2017-11-07 | — | — | CN | claimed |
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-12637435-B2 | Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof | FUJIFILM CORPORATION (JP) | 2026-05-26 | — | — | US | disclosed |
| CN-117659017-B | TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4739670-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2006009726-A2 | SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES | CYTOKINETICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | CYTOKINETICS, INCORPORATED | 2006-01-19 | — | — | US | disclosed |
| US-20050288273-A1 | Antibacterial agents | BOYER FREDERICK E JR | 2005-12-29 | — | — | US | disclosed |
| EP-1594865-A2 | ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004069832-A2 | ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040067531-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | SUGEN, INC. | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | TNNI3, MYLK2, TNNT2 | TDP1 3687/4885GPR35 3066/4885ALDH1A1 4250/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | TDP1 4803/4885GPR35 1805/4885ALDH1A1 2085/4885 |
| US-20040067531-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | ABL1, LCK, PNCK | TDP1 1403/4885GPR35 4104/4885ALDH1A1 3893/4885 |
| US-20050288273-A1 | Antibacterial agents | MRPL21, RPN2, FBL | TDP1 2355/4885GPR35 4537/4885ALDH1A1 637/4885 |
| US-12637435-B2 | Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof | CBR1, DHODH, CBR3 | TDP1 2604/4885GPR35 3504/4885ALDH1A1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.